Merger and acquisition (M&A) transactions remain prevalent in the medical device manufacturing industry in many forms—larger organizations making bolt-on acquisitions of smaller, innovative companies and/or businesses, mergers of equals, private equity deals, and medical product outsourcing providers grabbing specialty businesses to round out their offerings on the journey to full service.
To help our readers stay up to date about the medical device market’s evolution, MPO will catalog these M&A transactions throughout the year. We hope this will be a helpful resource!
GE HealthCare—SOFIE Biosciences
GE HealthCare is acquiring SOFIE Biosciences, a U.S.-based contract manufacturer of PET radiopharmaceuticals, from Trilantic North America. The deal establishes a footprint for GE HealthCare in the time-critical “final mile” of U.S. PET radiopharmaceutical supply, while also enabling the company’s PDx segment to participate in other high-growth areas outside its own product portfolio.
Date of Announcement: Oct. 7, 2026
Value: $945 million
Terumo Neuro—Arsenal Medical
Arsenal’s claim to fame is NeoCast, an investigational liquid embolic technology to treat chronic subdural hematoma. The solvent-free, non-adhesive biomaterial is designed to embolize the middle meningeal artery with controlled delivery and predictable distal penetration.
Date of Announcement: September 29, 2026
Value: Not disclosed
Precera Medical—Additive Metal Services
The contract development and manufacturing organization (CDMO) gains metal injection molding (MIM) and sinter-based additive manufacturing for its end-to-end offering.
Date of Announcement: September 10, 2026
Value: Not disclosed
Nolato—Unitron Group BV
Unitron is a Dutch CDMO that manufactures complex mechatronic and electronic equipment, including ventilation, electrophysiology, optics, heating, and printed electronics.
Date of Announcement: September 1, 2026
Value: Not disclosed
Currier Plastics—Sage Product Development
Currier Plastics completes the strategic acquisition of Sage Product Development, an engineering, design, and development provider that helps its medical device customers take their products from concept to commercialization.
Date of Announcement: August 11, 2026
Value: Not disclosed
Teledyne Technologies—Varex Imaging
Teledyne Technologies has agreed to buy Varex Imaging. The deal stands to further increase Teledyne’s exposure to the healthcare market.
Date of Announcement: August 10, 2026
Value: ~$1.1 billion
Kohlberg, Montagu—Teleflex Medical OEM (Ingenyx)
Teleflex completed the divestiture of its OEM business to investment firms Montagu and Kohlberg. The newly independent OEM business also announced its rebrand as Ingenyx.
Date of Announcement: August 3, 2026
Value: $1.5 billion
KKR—Integer Holdings Corporation
The contract development and manufacturing organization (CDMO) will become a portfolio company of investment firm KKR. Once completed, Integer will become a privately-held company.
Date of Announcement: August 3, 2026
Value: $5.7 billion
Cardinal Health—AdaptHealth, Strive Medical
The Dublin, Ohio-based company will acquire AdaptHealth’s Diabetes Health business and the entirety of Strive Medical, a multi-specialty provider focused on urology.
Date of Announcement: July 20, 2026
Value: $360 million
Leica Biosystems (Danaher)—StatLab
Established over 50 years ago, StatLab touts a portfolio of products for pre-analytical and analytical histology, ranging from specimen collection and tissue processing through slide preparation and staining.
Date of Announcement: July 14, 2026
Value: Not disclosed
Lōkahi Therapeutics—Glucotrack
The combined company integrates Lōkahi Therapeutics’ dual-engine model with Glucotrack’s technology platform to create a scalable, repeatable value creation framework.
Date of Announcement: July 14, 2026
Value: Not disclosed
Axel Johnson Inc.—Fort Wayne Metals
Fort Wayne Metals was founded in 1970. The Indiana-based company manufactures precision materials for medical devices and other crucial applications and boasts a reputation for innovation, quality, and deep partnerships with customers.
Date of Announcement: July 13, 2026
Value: Not disclosed
Resmed—Frazier Healthcare Partners
Resmed is selling its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on healthcare. The deal is part of Resmed’s 2030 strategy to focus on high-growth, scalable opportunities in sleep health, breathing health, and connected home-based healthcare.
Date of Announcement: July 8, 2026
Value: Not disclosed
Cretex Medical—Holland Molds
Cretex Medical has acquired select assets and capabilities of Holland Molds Inc. in Wadena, Minn. Neither company disclosed the deal’s terms. Known for its excellent quality and dedication to customer satisfaction, Holland provides sophisticated tooling for plastic injection molding.
Date of Announcement: June 16, 2026
Value: Not disclosed
Spectrum Vascular—Piccolo Medical
Piccolo’s real-time catheter guidance leverages proprietary blood flow sensing technology to guide catheter tip placement, removing the need for confirmatory chest X-rays.
Date of Announcement: June 11, 2026
Value: Not disclosed
Novanta—Riverpoint Medical
Riverpoint Medical is a developer, designer, and manufacturer of advanced surgical fibers and related technologies, offering private-label minimally invasive surgical consumables and instruments for markets including sports medicine, trauma, and cardiovascular surgery.
Date of Announcement: June 9, 2026
Value: $1.2 billion upfront, $250 milestone payment in Q2 2027
Cordica Medical—RapidWerks Micro Molding
The deal adds dedicated, automated micro molding for mass production to Cordica’s integrated design and manufacturing platform. This includes equipment designed for repeatable and robust shot-size accuracy and for producing parts that consistently weigh a fraction of a gram.
Date of Announcement: June 4, 2026
Value: Not disclosed
Olympus—BioProtect
BioProtect develops implant technologies to improve prostate cancer care and boost patients’ quality of life. Its flagship Balloon Spacer system provides consistent spacing between the prostate and other critical structures to protect healthy tissues during prostate cancer radiation therapies.
Date of Announcement: May 26, 2026
Value: $270 million
Endologix—Surmodics
Endologix acquired Surmodics’ Pounce system, an FDA-cleared mechanical thrombectomy system for non-surgical removal of thrombi and emboli from peripheral arteries.
Date of Announcement: May 19, 2026
Value: Not disclosed
Boston Scientific—MiRus
Boston Scientific invested for a 34% stake in MiRus, a company that developing and commercializing biomaterials, implants, and procedural solutions to treat cardiovascular and orthopedic diseases, including the Siegel balloon expandable TAVR.
Date of Announcement: May 18, 2026
Value: $1.5 billion
Artivion—Endospan
Artivion gains the Nexus aortic arch system, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair.
Date of Announcement: May 18, 2026
Value: $175 million, potential for up to further $200 million contingent on commercial performance
Roche—PathAI
PathAI is a U.S.-based company that specializes in digital pathology and AI-powered tech for pathology labs and the biopharma industry.
Date of Announcement: May 6, 2026
Value: $750 million upfront, further milestone payments up to $300 million
Johnson & Johnson—Atraverse Medical
Atraverse’s Hotwire transseptal access system is an FDA-cleared RF guidewire and generator system used for more confidence and control when accessing the left atrium.
Date of Announcement: April 24, 2026
Value: Not disclosed
Stereotaxis—Robocath
Merging Stereotaxis’ magnetic navigation tech and Robocath’s mechanical robotic system creates a differentiated fully robotic solution for endovascular surgery.
Date of Announcement: April 15, 2026
Value: $20 million upfront, contingent payments of up to $25 million
Stryker—Amplitude Vascular Systems
Amplitude Vascular Systems Inc. (AVS) is a privately held medical technology firm developing a next-generation intravascular lithotripsy (IVL) platform for treating calcified peripheral arterial disease.
Date of Announcement: April 13, 2026
Value: Not disclosed
Windjammer Capital—PrecisionX Group
The partnership marks a significant milestone in PrecisionX’s growth trajectory and strengthens the company’s ability to serve customers across its core end markets.
Date of Announcement: April 1, 2026
Value: Not disclosed
embecta—Owen Mumford
Owen Mumford’s products include a quickly growing pharmaceutical services portfolio built on historic autoinjector success with established pharma companies.
Date of Announcement: March 19, 2026
Value: £150 million ($199.4 million)
end of the note/
